What home care instructions should be provided to a patient after transcatheter aortic valve replacement (TAVR)?

Post-TAVR Home Care Instructions

Patients discharged after TAVR should receive dual antiplatelet therapy (aspirin 75-100 mg daily lifelong plus clopidogrel 75 mg daily for 3-6 months), have structured follow-up appointments scheduled (TAVR team at 30 days, cardiologist at 6 months), be educated about access site monitoring, encouraged to mobilize early and engage in physical activity, and instructed on optimal dental hygiene with endocarditis prophylaxis per AHA/ACC guidelines. 1

Medication Management

Antithrombotic Therapy:

• Aspirin 75-100 mg daily for life - this is non-negotiable for all TAVR patients 1
• Clopidogrel 75 mg daily for 3-6 months post-procedure 1
• Consider warfarin (INR 2.0-2.5) if the patient has atrial fibrillation or is at risk for venous thromboembolism 1
• Resume all appropriate preoperative cardiac medications promptly 1

Comorbidity Management: Continue medications for coronary disease, hypertension, heart failure, and arrhythmias as these significantly impact outcomes in this elderly, high-comorbidity population 1

Activity and Mobilization

Early mobilization is critical - patients should be encouraged to move as soon as the access site allows 1. Physical activity should be actively promoted, not just "as tolerated." 1

Cardiac rehabilitation is strongly recommended as it has been shown to:

• Improve exercise capacity
• Enhance quality of life
• Moderate frailty (present in >50% of TAVR patients)
• Increase survival 2, 3

Approximately one-third of TAVR patients require transitional care facilities, so physical and occupational therapy assessments should guide discharge planning 3

Access Site Care

Monitor the groin or thorax access site for:

• Bleeding
• Hematoma formation
• Pseudoaneurysm development 1

Patients should be instructed to immediately report any swelling, pain, discoloration, or bleeding at the access site. If there's concern for pseudoaneurysm, ultrasound evaluation is indicated 1

Follow-Up Schedule

Structured, coordinated follow-up is essential given that readmission rates exceed 40% in the first year, with 60% due to non-cardiac causes 1:

• TAVR team at 30 days - includes echocardiography and ECG 1
• Primary cardiologist at 6 months, then annually 1
• Primary care physician or geriatrician at 3 months, then as needed 1
• More frequent visits if symptoms change or if transient conduction abnormalities were noted 1

Coordination among the TAVR team, primary cardiologist, and primary care physician is mandatory to optimize outcomes 1

Monitoring for Complications

Neurological monitoring: Patients and caregivers should be educated about stroke symptoms given the 2-3% 30-day stroke risk 3

Cardiac conduction issues:

• 8-25% risk of permanent pacemaker requirement depending on valve type 3
• Consider 24-hour ECG monitoring if bradycardia develops 1
• Annual ECG is standard 1

Laboratory monitoring:

• Blood counts, metabolic panel, renal function should be monitored 1
• Assess pulmonary, renal, GI, and neurological function annually or as needed 1

Dental Care and Endocarditis Prophylaxis

Optimal dental hygiene must be emphasized - this is a prosthetic valve and carries endocarditis risk 1

Antibiotic prophylaxis per AHA/ACC guidelines should be provided for dental procedures 1

Patient Education Priorities

Educate patients about:

• Medication adherence - particularly the importance of lifelong aspirin
• Warning signs requiring immediate attention: chest pain, shortness of breath, syncope, stroke symptoms, access site complications
• The importance of all scheduled follow-up appointments - outcomes depend heavily on overall health management, not just valve function 1
• Lifestyle modifications including cardiac risk factor reduction 1

Common Pitfalls to Avoid

Do not discharge patients without:

• Scheduled follow-up appointments already made 1
• Clear written instructions about medications, especially antiplatelet therapy duration
• Access site care instructions specific to their approach (transfemoral vs transapical/transaortic)
• Contact information for urgent concerns

Remember: Early discharge (within 72 hours) is safe in selected transfemoral TAVR patients and does not increase 30-day mortality, bleeding, pacemaker implantation, or rehospitalization rates 1. In real-world practice, 73% can be discharged the day after TAVR and 89% within 48 hours 4. However, this requires appropriate patient selection and robust outpatient follow-up infrastructure.

The key to successful post-TAVR outcomes is recognizing that these patients are elderly with multiple comorbidities - the valve replacement addresses only one problem. Comprehensive, coordinated care addressing all health issues is what ultimately determines quality of life and survival 1.